To overcome regulatory hurdles for "N-of-1" medicines, researchers are using an "umbrella clinical trial" strategy. This approach keeps core components like the delivery system constant while only varying the patient-specific guide RNA, potentially allowing the FDA to approve the platform itself, not just a single drug.

The FDA issued Complete Response Letters for both REGENXBIO's gene therapy and DISC Medicine's oral drug, signaling high scrutiny for accelerated approvals. The agency specifically cited concerns over the relevance of surrogate endpoints and required more robust clinical trial data, highlighting the risks of relying on non-traditional approval pathways.

Despite the FDA leadership co-authoring an editorial supporting single-trial approvals, the industry is skeptical. The agency's recent inconsistent actions mean no executive or investor can confidently build a development strategy or financial model based on this policy, rendering the announcement largely ineffective.

The FDA issued guidance supporting minimal residual disease (MRD) as an approval endpoint in multiple myeloma. This directly contradicts the CBER division’s recent rejections of drugs based on single-arm response rates, creating a "schizophrenic" and unpredictable regulatory landscape for developers.

Developers often test novel agents in late-line settings because the control arm is weaker, increasing the statistical chance of success. However, this strategy may doom effective immunotherapies by testing them in biologically hostile, resistant tumors, masking their true potential.

In solid tumor immunotherapy, significant efficacy gains almost always correlate with increased toxicity. This study's claim of nearly doubled progression-free survival with identical toxicity rates is biologically implausible and was a primary reason for skepticism, even before analyzing the trial's methodology.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.

Corcept Therapeutics' drug relacorilant exemplifies drug development's volatility. Within the same reporting period, the drug showed positive Phase 3 overall survival data in ovarian cancer but received an FDA rejection for Cushing's syndrome. This stark contrast highlights how a single drug's clinical and regulatory success is entirely indication-specific.

Following public pressure, the FDA seems to be entering a "kinder, gentler" era for orphan drugs. Reports indicate agency leaders are proactively meeting with companies post-rejection to find a path forward. This suggests a potential shift towards more flexibility for therapies in rare diseases with high unmet need, even with imperfect data.